10x Genomics reported Q2 2026 revenue of $151 million, up 3% from last year excluding patent settlement income. The company acquired Proteintech Genomics to enhance its multiomics capabilities and announced collaborations to advance cancer diagnostics. Despite a net loss of $17.9 million due to lower settlement gains, 10x Genomics raised its full-year revenue guidance to $610-$630 million, signaling confidence in growth prospects.
10x Genomics will use Lunit's AI-powered pathology platform, Lunit SCOPE IO, to analyze H&E pathology images alongside its spatial molecular data in oncology research. This integration aims to improve understanding of tumor biology and identify bioma...
Torex Gold Resources reported a strong Q2 with a net profit of $113.8 million and earnings per share of $1.22, driven by higher gold prices and increased production in Mexico. The company generated $98 million in free cash flow, holds $169 million in...
